IL314395A - Bispecific anti-CD47 and anti-PD-L1 activatable proteins and their uses - Google Patents

Bispecific anti-CD47 and anti-PD-L1 activatable proteins and their uses

Info

Publication number
IL314395A
IL314395A IL314395A IL31439524A IL314395A IL 314395 A IL314395 A IL 314395A IL 314395 A IL314395 A IL 314395A IL 31439524 A IL31439524 A IL 31439524A IL 314395 A IL314395 A IL 314395A
Authority
IL
Israel
Prior art keywords
proteins
activatable bispecific
activatable
bispecific anti
bispecific
Prior art date
Application number
IL314395A
Other languages
English (en)
Hebrew (he)
Original Assignee
Centessa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals Uk Ltd filed Critical Centessa Pharmaceuticals Uk Ltd
Publication of IL314395A publication Critical patent/IL314395A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL314395A 2022-01-31 2023-01-31 Bispecific anti-CD47 and anti-PD-L1 activatable proteins and their uses IL314395A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263305003P 2022-01-31 2022-01-31
US202263309759P 2022-02-14 2022-02-14
US202263342283P 2022-05-16 2022-05-16
US202263348842P 2022-06-03 2022-06-03
PCT/EP2023/052366 WO2023144423A1 (en) 2022-01-31 2023-01-31 Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof

Publications (1)

Publication Number Publication Date
IL314395A true IL314395A (en) 2024-09-01

Family

ID=85199086

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314395A IL314395A (en) 2022-01-31 2023-01-31 Bispecific anti-CD47 and anti-PD-L1 activatable proteins and their uses

Country Status (9)

Country Link
US (1) US20250002585A1 (https=)
EP (1) EP4473012A1 (https=)
JP (1) JP2025504955A (https=)
KR (1) KR20240137084A (https=)
AU (1) AU2023210844A1 (https=)
CA (1) CA3251615A1 (https=)
IL (1) IL314395A (https=)
MX (1) MX2024009251A (https=)
WO (1) WO2023144423A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
CN111212852A (zh) 2017-08-18 2020-05-29 超人肆有限公司 结合剂
US20240124889A1 (en) * 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
CN116390939A (zh) * 2020-08-04 2023-07-04 埃克塞里艾克西斯公司 多重特异性结合剂及其用途

Also Published As

Publication number Publication date
JP2025504955A (ja) 2025-02-19
US20250002585A1 (en) 2025-01-02
MX2024009251A (es) 2024-08-06
AU2023210844A1 (en) 2024-08-01
CA3251615A1 (en) 2023-08-03
EP4473012A1 (en) 2024-12-11
WO2023144423A1 (en) 2023-08-03
KR20240137084A (ko) 2024-09-19

Similar Documents

Publication Publication Date Title
ZA202208807B (en) Anti-tigit antibodies and usage method
IL308808A (en) Antibodies against CCR8 and their uses
GB202001196D0 (en) Activatable protein constructs and uses thereof
EP3969484A4 (en) ANTI-CD47/ANTI-PD-L1 MULTIPLE ANTIGEN BINDING PROTEINS AND METHODS OF USE
CA3287794A1 (en) Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
GB2610467B (en) Anti-CLL1 antibody and application thereof
EP3847196A4 (en) BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
GB202017058D0 (en) Antibodies and uses thereof
AU2021383901A9 (en) Bispecific antibody and use thereof
IL307267A (en) ANTI-CD122 antibodies and their uses
IL319931A (en) Anti-CD122 antibodies and their uses
IL310662A (en) Anti-CD161 antibodies and their uses
IL307940A (en) Anti-ADGRE2 antibodies and their uses
EP4190816A4 (en) ANTI-CD47 MONOCLONAL ANTIBODY AND ITS USE
EP4382541A4 (en) BISPECIFIC ANTIBODY AND USE THEREOF
EP3820895A4 (en) EFFICIENTLY EXPRESSED EGFR AND PD-L1 BINDER PROTEINS
IL315351A (en) ANTI-CD39 antibodies and their use
IL307939A (en) Anti-CLEC12A antibodies and uses thereof
EP4119571A4 (en) NEW BISPECIFIC PROTEIN AND USE THEREOF
IL314395A (en) Bispecific anti-CD47 and anti-PD-L1 activatable proteins and their uses
IL315768A (en) Bispecific anti-CD3 and anti-PD-L1 activatable proteins and their uses
IL312584A (en) ANTI-VISTA antibodies and their uses
HK40119555A (en) Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof
IL320972A (en) Anti-TFR1 antibodies and their uses
IL307233A (en) Anti-SEMA3A antibodies and uses thereof